Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality

被引:0
作者
Montserrat Vera-Llonch
Derek Weycker
Andrew Glass
Sue Gao
Rohit Borker
Angie Qin
Gerry Oster
机构
[1] Policy Analysis Inc (PAI),
[2] Kaiser Permanente Northwest,undefined
[3] Amgen Inc,undefined
来源
BMC Cancer | / 11卷
关键词
Cost; metastatic breast cancer; chemotherapy; burden of illness;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 103 条
[1]  
Glass AG(2007)Breast cancer incidence, 1980-2006: Combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status J Natl Cancer Inst 99 1152-1161
[2]  
Lacey JV(2008)Factors predictive of response to hormone therapy in breast cancer Tumori 94 370-383
[3]  
Carreon JD(1998)Drug therapy: Treatment of breast cancer N Engl J Med 339 974-984
[4]  
Hoover RN(2010)Triple-negative breast cancer: role of specific chemotherapy agents Cancer J 16 53-61
[5]  
Rastelli F(2003)Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer Cochrane Database Syst Rev 2 CD002747-223
[6]  
Crispino S(2008)Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: current status and future opportunities Clin Breast Cancer 8 215-10874
[7]  
Hortobagyi GN(2001)Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 10869-8423
[8]  
Isakoff SJ(2003)Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci USA 100 8418-10398
[9]  
Wilcken N(2003)Breast cancer classification and prognosis based on gene expression profiles from a population-based study Proc Natl Acad Sci USA 100 10393-209
[10]  
Hornbuckle J(2009)The costs of treating breast cancer in the US Pharmacoeconomics 27 199-207